Finerenone Reduces Clinical Events in Patients With Heart Failure Regardless of CHD History

Why It Matters

Consistent efficacy across CHD status expands finerenone’s appeal for HFmrEF/HFpEF patients, a cohort with few proven therapies, while the lack of impact on stroke or MI underscores the need for additional anti‑ischemic measures.

Key Takeaways

• Finerenone cut cardiovascular death/HF events in HFmrEF/HFpEF patients
• Benefit held true regardless of prior coronary heart disease
• No reduction in stroke, MI, or atherothrombotic outcomes observed
• CHD patients showed higher baseline risk and event rates than non‑CHD

Pulse Analysis

Finerenone, a non‑steroidal mineralocorticoid receptor antagonist, has emerged as a promising option for patients with heart‑failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF). This population often carries coronary heart disease, which amplifies morbidity and limits the effectiveness of conventional heart‑failure therapies. By blocking aldosterone‑driven fibrosis and inflammation, finerenone targets a pathophysiologic pathway that is not addressed by standard neuro‑hormonal agents, positioning it as a complementary treatment in a crowded therapeutic landscape.

The FINEARTS‑HF trial enrolled 6,001 participants, nearly 54% of whom reported prior CHD. Across both subgroups, finerenone achieved a 14‑20% relative reduction in the primary composite of cardiovascular death and heart‑failure events, with rate ratios of 0.86 for CHD patients and 0.80 for those without CHD. Interaction testing showed no statistically significant difference, confirming that the drug’s benefit is robust regardless of coronary disease history. These findings are particularly salient because CHD patients demonstrated higher baseline NT‑proBNP levels and event rates, highlighting finerenone’s capacity to improve outcomes in a higher‑risk cohort.

Despite the encouraging heart‑failure data, finerenone did not meaningfully affect atherothrombotic endpoints such as stroke or myocardial infarction. This neutral effect suggests that clinicians will still need to rely on antiplatelet or anticoagulant strategies to mitigate ischemic risk. The trial’s results are likely to influence prescribing patterns, encouraging broader adoption of finerenone in HFpEF/HFmrEF protocols while prompting further research into combination regimens that address both heart‑failure progression and atherosclerotic complications.